TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tvardi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.97−0.04 (-3.96%)
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tvardi Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Market Cap | $12.94M | $164.85M |
| Enterprise Value | -$2.83M | $87.06M |
| PB Ratio | 1.54 | 2.03 |
| P/TBV Ratio | 1.60 | 2.31 |
Income (trailing twelve months)
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$27.21M | -$21.44M |
| Net Income | -$26.06M | -$22.46M |
| EBITDA | -$27.11M | -$16.91M |
Returns
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -126.2% | -53.1% |
| Return on Assets (ROA) | -85.1% | -41.0% |
| Return on Capital Employed (ROCE) | -323.7% | -37.8% |
Balance sheet
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $15.77M | $62.42M |
| Net Cash (Debt) | $15.77M | $15.68M |
| Net Cash Per Share | $1.18 | $0.66 |
| Equity (Book Value) | $8.38M | $48.79M |
| Book Value Per Share | $0.63 | $1.36 |
| Tangible Book Value | $8.09M | $23.06M |
| Working Capital | $7.96M | $75.77M |
Financial position
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.87 | 3.30 |
| Quick Ratio | 1.73 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$25.03M | -$12.35M |
Efficiency
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.17M | -$703.34K |
| Employee Count | 12 | 74 |
Dividends and yields
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -201.4% | -22.7% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 13,338,900 | 58,179,650 |
| Shares Change (YoY) | 132.0% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 11,252,900 | 49,173,100 |
| Shares Held by Insiders | 15.6% | 11.6% |
| Shares Held by Institutions | 16.7% | 59.4% |
Scores
| Measure | Tvardi Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -13.62 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Tvardi Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.